Research and Markets (http://www.researchandmarkets.com/reports/c91774) has announced the addition of "Germany Pharmaceuticals and Healthcare Report Q2 2008" to their offering.
The Germany Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Germany's pharmaceuticals and healthcare industry.
Germany's pharmaceutical market was worth approximately US$48.9bn in 2007, making it the largest in Europe. Unsurprisingly, for such a mature market, growth will be steady rather than spectacular, with drug expenditure reaching a value of US$57.2bn in 2012. This represents a compound annual growth rate (CAGR) of 3.19%.
The biggest change this quarter has been the author's introduction of forecasts in the medical device market. In 2007, the authors estimated that the medical equipment market was worth approximately US$13bn and should reach a value of US$15.1bn by 2012. This represents a CAGR of 3%, a slightly lower rate than the pharmaceuticals market. Going forward, growth should be driven primarily by large, top-end medical equipment due to Germany's technological sophistication in this area.
Elsewhere, Germany's drug discount contracts have come under fire from the German Association of Medicines Manufacturers (BAH), which claims that they are anti-competitive and will hurt small and medium-sized enterprises. The mandatory contracts were introduced to lower costs but have met with criticism from the drug industry calling for less regulation. It was expected that the reform would also be a stimulus to competition, but the larger firms have been given an unfair advantage as they have the financial muscle to undercut their rivals.
Germany retains second place in the Business Environment Rankings for the Western European region, just behind Switzerland. The country benefits from a large internal market and a high per capita spend. The local industry is also traditionally strong and technologically advanced. However, a stringent focus of cost-containment is harming innovation and presenting a barrier to foreign direct investment (FDI), according to the research-based manufacturing sector. Many multinationals, such as France's Sanofi-Aventis are actually considering disinvesting in the country due to government pressure.
CONTENTS:
- Executive Summary
- Germany Pharmaceuticals And Healthcare Industry SWOT
- Germany Political SWOT
- Germany Economic SWOT
- Pharmaceutical Business Environment Ratings
- Table: Western Europe Pharmaceutical Business Environment Ratings
- Limits Of Potential Returns
- Risks To Realisation Of Returns
- Germany - Market
- Regulatory Regime
- Intellectual Property Developments
- Pricing And Reimbursement Issues
- Retail Industry
- Industry Developments
- Healthcare Sector
- Pharmaceutical Sector
- Domestic Industry
- Krankenkassen
- Foreign Industry
- Research And Development Sector
- Generics Sector
- Wholesaler Sector.
- Epidemiology
- Biotechnology Sector
- Industry Forecast Scenario
- Overall Market Forecast
- Table: German Drug Market Expenditure Forecasts
- Key Growth Factors - Industry
- Table: German Health Expenditure Indicators, 2004-2012
- Key Growth Factors - Macroeconomic
- Table: Germany - Economic Forecasts
- Patented Market Forecast
- Table: Germany's Branded Market Indicators, 2004-2012
- OTC Market Forecast
- Table: Germany's OTC Market Indicators, 2004-2012 (US$mn unless otherwise stated)
- Generics Market Forecasts
- Table: Germany's Generics And Branded Market Indicators, 2004-2012 55
- Export/Import Forecasts
- Table: Germany's Pharmaceuticals Exports And Imports, 2004-2012 (US$mn)
- Industry News
- Table: Leading German Medical Device Players
- Table: Germany's Medical Device Market Indicators, 2006-2012 (US$bn unless otherwise stated)
- Key Risks To our Forecast Scenario
- Competitive Landscape
- Company Profiles
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co
- Bayer
- Boehringer Ingelheim
- Our Forecast Modelling
- How We Generate Our Industry Forecasts
- Pharmaceutical Industry
- Pharmaceutical Business Environment Ratings Methodology
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
Companies Mentioned:
- GlaxoSmithKline (GSK)
- Pfizer
- Novartis
- Sanofi-Aventis
- Merck & Co
- Bayer
- Boehringer Ingelheim
For more information visit http://www.researchandmarkets.com/reports/c91774
